Company
Rua Bioscience Ltd
Headquarters: Gisborne, New Zealand
Employees: 30
Market Cap
NZ$18.8 Million
NZD as of Jan. 1, 2024
US$11.9 Million
Rua Bioscience Ltd Categories
New Zealand Healthcare Drug Manufacturers—Specialty & GenericNew Zealand Healthcare New Zealand Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $89.09 B |
| MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
| Takeda Pharmaceutical Company Limited | $47.71 B |
| Haleon plc | $38.90 B |
| PPD, Inc. | $16.58 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Rua Bioscience Limited, a pharmaceutical company, engages in the research, development, cultivation, and manufacturing of cannabinoid derived medicines in New Zealand and internationally. The company was formerly known as Hikurangi Cannabis Company Limited and changed its name to Rua Bioscience Limited in October 2019. Rua Bioscience Limited was founded in 2016 and is headquartered in Gisborne, New Zealand.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Rua Bioscience Ltd has the following listings and related stock indices.
Stock: NZX: RUA wb_incandescent